Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. - Wikidata - awgldk - TriplyDB

Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer.

Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer.

http://www.wikidata.org/entity/Q33418642

about

Small cell lung cancer (SCLC): no treatment advances in recent years Treatment for small cell lung cancer, where are we now?-a review Targeting angiogenesis in small cell lung cancer Amrubicin for relapsed small-cell lung cancer: a systematic review and meta-analysis of 803 patients New and emerging developments in extensive-stage small cell lung cancer therapeutics Checkpoint inhibitors in lung cancer: latest developments and clinical potential A Phase II Study of Weekly Paclitaxel Plus Gemcitabine as a Second-Line Therapy in Patients with Metastatic or Recurrent Small Cell Lung Cancer.Safety of topotecan monotherapy for relapsed small cell lung cancer patients with pre-existing interstitial lung disease.Phase II study of amrubicin at a dose of 45 mg/m2 in patients with previously treated small-cell lung cancer.Phase 2 trial of the topoisomerase II inhibitor, amrubicin, as second-line therapy in patients with metastatic urothelial carcinoma.Meta-analysis of the role of bevacizumab in extensive stage small cell lung cancer.Amrubicin monotherapy may be an effective second-line treatment for patients with large-cell neuroendocrine carcinoma or high-grade non-small-cell neuroendocrine carcinoma.A prospective pilot study of genome-wide exome and transcriptome profiling in patients with small cell lung cancer progressing after first-line therapy A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo Chemotherapy for small cell lung cancer: a comprehensive review Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer.Interlinked DNA nano-circles for measuring topoisomerase II activity at the level of single decatenation events.Efficacy of different monotherapies in second-line treatment for small cell lung cancer: a meta-analysis of randomized controlled trials.Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?[68Ga]Pentixafor-PET/CT for imaging of chemokine receptor 4 expression in small cell lung cancer--initial experience Albumin-bound paclitaxel for the treatment of refractory or relapsed small-cell lung cancer.Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets.Clinical impact of post-progression survival on overall survival in elderly patients with extensive disease small-cell lung cancer.Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumors.Relapsed small cell lung cancer: treatment options and latest developments.Retrospective analysis of outcomes and prognostic factors of chemotherapy for small-cell lung cancer.Topotecan for Relapsed Small-cell Lung Cancer: Systematic Review and Meta-Analysis of 1347 Patients.Optimal drugs for second-line treatment of patients with small-cell lung cancer.Prospect and progress of personalized peptide vaccinations for advanced cancers.Real-Time Reverse-Transcription Quantitative Polymerase Chain Reaction Assay Is a Feasible Method for the Relative Quantification of Heregulin Expression in Non-Small Cell Lung Cancer Tissue.The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer.Therapies in the pipeline for small-cell lung cancer.Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib.PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?Progress and challenges in the treatment of small cell lung cancer.Interstitial lung disease associated with amrubicin chemotherapy in patients with lung cancer: a single institutional study.A retrospective study of amrubicin monotherapy for the treatment of relapsed small cell lung cancer in elderly patients.Second line treatment of small cell lung cancer: more is better?Evaluation of factors associated with platinum-sensitivity status and survival in limited-stage small cell lung cancer patients treated with chemoradiotherapy.Paclitaxel as third-line chemotherapy for small cell lung cancer failing both etoposide- and camptothecin-based chemotherapy.

P2860

Q26767020-FC921D3A-7CDB-43E7-8737-9C323FEA05C7 Q26767023-2EFCC808-E230-48F4-AD75-A9B624CF7124 Q28068385-DD30F2F1-699D-487B-B782-AF0DEE02CE4C Q28072672-9AF59F90-B37C-47CA-9641-ADC1862A0445 Q28076304-7237DE9B-B00B-4719-B210-981C4DBB75C4 Q28076467-52E234BD-4C60-475E-86A7-77E392D7BA19 Q33423381-8EFD7A36-3CD7-4FA8-A6E3-56D24BB17B16 Q33424081-10F78264-4729-4DC9-B610-12B6D7400065 Q33424869-5FD0128C-ED25-49E5-AC53-6A41C5B50B04 Q33426694-ACFD8B75-6F19-4DD1-AF30-BE5F3F329679 Q33443519-CEDA231C-CBE3-455B-9963-AD15BA72E2CA Q33685826-3EF9A6F6-27A3-4757-B575-208D5FF780E8 Q33769203-BFA3A09D-160E-42F6-99D9-A67E0C0BC2F0 Q34491149-B3E1EB6D-4E8C-4FD7-A04F-2F693966AFAC Q35569379-ED365245-ADC7-4FEF-A500-575263C2F26A Q35984458-303E938C-4026-4536-A8CC-83443B7A9111 Q36379849-D277929F-5C8B-43A5-A662-58C2B0E165DE Q36412432-5B001D33-F332-4F9E-BC02-5A6A6F55C501 Q36811784-563C4459-28C1-41A6-832A-E5307BBCBDDB Q36962582-D93F9D23-65DD-4E6B-9C67-CA399AC926A2 Q37001700-BF1420C0-B4CF-47C6-B73F-DB72C03DADAC Q37045774-FD92E61C-5B83-49F8-8872-9688BA85CA91 Q37389608-071C560F-0512-43F4-A492-F5CC63B1CB79 Q37544686-38257182-3AD5-41A7-B316-A15129F326AB Q37598178-1CBF4E89-03C2-4924-B01E-AE947462F0FE Q37643545-DEA928B7-3505-410D-84C2-18F7EB042357 Q38612645-3E671ADA-8BA7-4170-AD78-3AB58CB8CE03 Q38734204-097AC4FE-D591-488B-A0DE-D00657A2DA7D Q38758988-0E939BCF-C913-416A-8107-45A543FAB80A Q38806218-2860E21C-4BCF-4FE8-8768-56B1DCC2D025 Q38847321-2D2BD458-3FE4-4FF2-9F65-7661F18B4A82 Q38871386-21912098-D2C0-4824-B820-7FC3DF7140ED Q38876644-3A79468A-A1DA-4CD3-BA75-6647F4B8F166 Q39033713-2371F98C-345E-4717-B314-F5D06853B0F3 Q39272825-3F52ABE6-FD24-4B68-A4A6-A7FC799DE58E Q39780381-EDDFBB34-A487-452D-A2B5-C24FB9592EE1 Q41537638-EDC9830C-C1E0-40A6-8425-51E0353844A4 Q42106835-62011ECA-CFDB-408C-8DC0-E49A9372BD2F Q43139088-4448FFC6-023E-471D-983F-1044264DD004 Q47163002-C85B0161-E0CF-4D8E-9477-BA4264BFCAAD

P2860

Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer.

http://www.wikidata.org/entity/Q33418642

description

2014 nî lūn-bûn

@nan

2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Randomized phase III trial of ...... s with small-cell lung cancer.

@ast

Randomized phase III trial of ...... s with small-cell lung cancer.

@en

type

label

Randomized phase III trial of ...... s with small-cell lung cancer.

@ast

Randomized phase III trial of ...... s with small-cell lung cancer.

@en

prefLabel

Randomized phase III trial of ...... s with small-cell lung cancer.

@ast

Randomized phase III trial of ...... s with small-cell lung cancer.

@en

P1433

Q33418642-2DB0663C-35C1-48CF-804B-3766C8C8D61B

P1476

Q33418642-81689232-4EAF-44F2-B1A0-A6EC8CB22003

P2093

Q33418642-1BA2D98C-C58D-4BFA-9C59-9E7657CB2F72

Q33418642-36D9F2AA-054D-44D9-AE0B-B3A242B0D153

Q33418642-3A47E7CD-DAD1-4A9D-B0F0-AEB84E61F7FE

Q33418642-40A70A93-6615-4B4F-AF63-B2F90DA0400D

Q33418642-622CB225-3558-4EA6-A523-3919F9D440ED

Q33418642-68AAB583-56EE-4FD7-89F5-2D27E437AA2A

Q33418642-73A27F41-9E72-4B4F-9F41-58B40FF944EA

Q33418642-782FEB87-54DF-4355-A170-75976BD3EFFD

Q33418642-8C7B8C3E-3B64-4D3B-B5C7-C7B2B4B581B8

Q33418642-A5646D38-AAD2-4FDE-B8F8-852F29DAD238

P304

Q33418642-C88CCE10-85DD-4DEC-AE8C-7A7039310F8C

P31

Q33418642-7C86869A-B291-443E-BE20-7A7E4317EEAB

P356

Q33418642-FB2AF236-3F97-42A6-8469-8968A4C4B700

P407

Q33418642-5080CA09-15AE-4F82-BDC3-15514143134E

P433

Q33418642-5359EEC1-6A1B-4C74-897A-1F9A7754A595

P478

Q33418642-52A1EFDE-81BF-4173-A2CF-AE3CF0E20495

P50

Q33418642-DA42B9C4-E9AA-4AE5-B9AC-A885D1D5BA24

P577

Q33418642-8AA208C1-03B9-4DD7-A947-D66C077669B0

P698

Q33418642-777D01BA-F7E1-4E47-98EC-5595021E6A96

P921

Q33418642-90231CC1-6754-4AEB-AE88-AD63AC09E6A1

P356

JCO.2013.54.5392

P1433

Journal of Clinical Oncology

P1476

Randomized phase III trial of ...... s with small-cell lung cancer.

@en

P2093

David R Spigel

http://www.w3.org/2001/XMLSchema#string

Frances A Shepherd

http://www.w3.org/2001/XMLSchema#string

Jeffrey Bubis

http://www.w3.org/2001/XMLSchema#string

Joachim von Pawel

http://www.w3.org/2001/XMLSchema#string

José M Trigo

http://www.w3.org/2001/XMLSchema#string

Jörg Mezger

http://www.w3.org/2001/XMLSchema#string

Kristiaan Nackaerts

http://www.w3.org/2001/XMLSchema#string

Léon Bosquée

http://www.w3.org/2001/XMLSchema#string

Manuel Domine

http://www.w3.org/2001/XMLSchema#string

Mark A Socinski

http://www.w3.org/2001/XMLSchema#string

P304

4012-4019

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2013.54.5392

http://www.w3.org/2001/XMLSchema#string

P407

P433

35

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-11-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25385727

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial